Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

A case of facial lipoatrophy secondary to lupus profundus managed with lipofilling technique

Valdatta L., Cherubino M., Tamborini F., Pellegatta I., Maggiulli F.

Prospective Study on Autoimmune Research, published in Case Rep Dermatol Med (2012) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Case Rep Dermatol Med (2012)
Reported sample size
—
Source database
Europe PMC
PMID
23304570
PMCID
PMC3529427
DOI
10.1155/2012/720518
Citations
3

Abstract (original English)

Facial lipoatrophy is one of the most difficult complication in the patients with lupus profundus. In this paper, we present a case of a 55-year-old woman affected by lupus profundus, with a grade V lipoatrophy, treated with lipofilling technique. No complications were observed and results at 12 months were stable, natural, and symmetric.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research